Private equity firm CVC eyes stock market listing - reports

Goldman Sachs working with the firm

Kathleen Gallagher
clock • 1 min read

Private equity giant CVC is working with Goldman Sachs on a stock market listing, according to reports from The Sunday Times.

However, people familiar with the matter told Bloomberg News the firm has not mandated banks and is discussing options internally. London-based CVC has $125bn in assets under management with minority positions in Premiership Rugby and Six Nations. It has also been trying to acquire stakes in top Italian and Spanish football leagues. $7.4trn and rising: Asset management's rush to private markets In November the private equity firm agreed to buy Unilever's tea business for €3.4bn. If CVC were to list in London it would be the fourth private equity firm to go public and would f...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot